Tourmaline Bio (NASDAQ:TRML) (NASDAQ:TRML) is a clinical-stage biopharmaceutical company focused on developing next-generation antibody therapeutics for oncology and immune-mediated diseases. The company’s proprietary glycoengineering platform is designed to optimize antibody effector functions and improve therapeutic indices by precisely modifying glycan structures. Headquartered in Cambridge, Massachusetts, Tourmaline Bio leverages cutting-edge research to advance a pipeline of novel monoclonal antibodies and antibody-drug conjugates aimed at addressing high unmet medical needs.
The company’s R&D strategy centers on enhancing antibody activity while minimizing off-target effects. By employing site-specific glycan remodeling, Tourmaline Bio seeks to bolster antibody-dependent cellular cytotoxicity and enhance tumor cell clearance. This platform approach supports both in-house candidate development and external partnerships, enabling collaborations with larger pharmaceutical companies to co-develop or out-license lead assets. The flexibility of the platform allows for rapid iteration and optimization across multiple therapeutic targets.
Tourmaline Bio’s pipeline features several preclinical and clinical-stage assets, including a bispecific antibody in Phase 1 development for solid tumors and an engineered anti-CD20 antibody for B-cell malignancies. The company has also initiated exploratory programs in autoimmune indications, where glycoengineered antibodies may offer improved safety profiles over conventional biologics. With manufacturing scaled through state-of-the-art CMC capabilities in North America and Europe, Tourmaline Bio maintains strategic partnerships to support global clinical development and eventual commercial readiness.
Founded in 2018 by a team of biochemists and immunologists, Tourmaline Bio is led by President and CEO Michael Scharpe, whose prior leadership roles include senior management positions at established biotech firms. The executive team is rounded out by Nancy Lee, Chief Financial Officer, and Dr. David Normoyle, Chief Scientific Officer, each bringing extensive experience in antibody drug discovery and corporate finance. Together, they guide Tourmaline Bio’s mission to translate innovative antibody engineering into transformative therapies for patients worldwide.
